Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 1.32% | 697.33 | 2.6% | $644.85m | |
| MRNA | Moderna, Inc. | -0.55% | 123.64 | 0.0% | $634.51m | |
| AMGN | Amgen, Inc. | -0.34% | 226.97 | 1.4% | $624.69m | |
| GILD | Gilead Sciences, Inc. | -1.43% | 62.86 | 1.0% | $494.49m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.01% | 283.45 | 1.9% | $355.83m | |
| ILMN | Illumina, Inc. | -1.61% | 190.38 | 3.2% | $291.37m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -5.81% | 4.05 | 0.7% | $283.11m | |
| BIIB | Biogen, Inc. | -1.42% | 197.78 | 1.8% | $184.42m | |
| SAVA | Cassava Sciences, Inc. | -18.00% | 41.87 | 0.0% | $173.71m | |
| BNTX | BioNTech SE | -1.27% | 128.35 | 0.0% | $100.39m | |
| NRBO | NeuroBo Pharmaceuticals, Inc. | -6.44% | 15.54 | 0.0% | $89.03m | |
| NVAX | Novavax, Inc. | -6.42% | 21.00 | 75.6% | $85.66m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.09% | 84.84 | 4.2% | $76.07m | |
| EXAS | EXACT Sciences Corp. | -2.74% | 33.41 | 17.6% | $71.49m | |
| CRSP | CRISPR Therapeutics AG | -2.68% | 63.16 | 0.6% | $69.53m |
Company Profile
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.